Objective: To demonstrate the efficacy of the subconjunctival administration of bevacizumab in the treatment of corneal neovascularization. Methods: This was and interventional, prospective, not randomized study involving 7 eyes with corneal neovascularization due to different causes. All patients received a single dose of 2.5 mg of subconjunctival bevacizumab. Corneal vascularization appearance was photographically documented. Results: 5 of 7 eyes showed an average of 60% regression in the corneal neovascularization as we measured the length of the visible vasculature. Conclusion: Subconjunctival injection of bevacizumab allows an important regression in the corneal neovascularization.